DalsgaardS, KvistAP, LeckmanJF, NielsenHS, SimonsenM: Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: A nationwide prospective cohort study. J Child Adolesc Psychopharmacol, 24:302–310, 2014.
2.
HamiltonRM, RosenthalE, Hulpke-WetteM, GrahamJGI, SergeantJ: Cardiovascular considerations of attention deficit hyperactivity disorder medications: A report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young, 22:63–70, 2012.
3.
HammernessPG, PerrinJM, Shelley-AbramsonR, WilenTE: Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: Update and clinical recommendations. J Am Acad Child Adolesc Psychiatry, 50:978–990, 2011.
4.
WestoverAN, HalmEA: Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovascular Disorders, 12:41, 2012.
5.
WintersteinAG, GerhardT, KubilisP, SaidiA, LindenS, CrystalS, ZitoJ, ShusterJJ, OlfsonM: Cardiovascular safety of central nervous system stimulants in children and adolescents: Population based cohort study. BMJ, 345:e4627:1–12, 2012.
